Anthem Biosciences, an India-based contract development and manufacturing organization (CDMO), has filed for a public offering valued at approximately 33.95 billion rupees ($397 million). The move, announced at the end of 2024, aims to support the company’s ongoing expansion in
Anthem Biosciences is a company operating in the pharmaceutical industry. Anthem Biosciences started in 2006 as a CRO (Contract Research Organization) in research and development of pharmaceutical and nutrition products. Our state-of-the-art cGMP R&D facilities with over 800 scientists allow
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
